<DOC>
	<DOCNO>NCT00395421</DOCNO>
	<brief_summary>This study conduct see investigational medication , valopicitabine , safe use combination ribavirin , drug approve FDA treat hepatitis C infection .</brief_summary>
	<brief_title>Study Evaluate Drug-drug Interaction Between Valopicitabine Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Documented clinical history compatible chronic hepatitis C compensate liver disease Has previously receive antiviral therapy hepatitis C infection Other protocoldefined inclusion criterion may apply . Patient pregnant breastfeeding Patient coinfected hepatitis B virus and/or HIV Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>treatment-naive</keyword>
</DOC>